Search for: "James Yoon" Results 1 - 20 of 60
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
10 Apr 2024, 5:02 am by Beatrice Yahia
James Lankford (R-Okla.) and a group of Republican and Democratic members of the House. [read post]
3 Oct 2023, 2:00 am by Seán Binder
John Yoon reports for the New York Times. [read post]
8 Aug 2023, 2:14 am by Seán Binder
Dasl Yoon report for the Wall Street Journal. [read post]
17 May 2023, 3:17 am by Seán Binder
 The agreement was reached a day after Ukraine’s first lady, Olena Zelenska, met South Korean President Yoon Suk Yeol to request military assistance. [read post]
24 Apr 2023, 3:02 am by Seán Binder
” Daniel Michaels and James Marson report for the Wall Street Journal. [read post]
19 Apr 2023, 2:53 am by Seán Binder
  South Korea might extend its support for Ukraine beyond humanitarian and economic aid if it comes under a large-scale civilian attack, President Yoon Suk Yeol said. [read post]
27 Mar 2023, 4:06 am by Seán Binder
Dasl Yoon reports for the Wall Street Journal. [read post]
22 Mar 2023, 4:51 am by Emma Snell
Dasl Yoon reports for the Wall Street Journal. [read post]
16 Mar 2023, 5:04 am by Seán Binder
James Shotter reports for the New York Times. [read post]
20 Jan 2023, 4:28 am by Emma Snell
Corinne Ramey and James Fanelli report for the Wall Street Journal. [read post]
10 Jan 2023, 2:39 pm by Jason Rantanen
Lemley, Erik Oliver, Kent Richardson, James Yoon, & Michael Costa, Patent Purchases and Litigation Outcomes, 2016 Patently-O Patent Law Journal 15 (Lemley.2016.PatentMarket) Bernard Chao and Amy Mapes, An Early Look at Mayo’s Impact on Personalized Medicine, 2016 Patently-O Patent Law Journal 10 (Chao.2016.PersonalizedMedicine) James E. [read post]
1 Nov 2022, 4:37 am by Emma Snell
Signup to receive the Early Edition in your inbox here. [read post]
5 Jul 2022, 7:12 am by Philip Mousavizadeh
James Bikales reports for the Washington Post. [read post]
25 Apr 2022, 4:41 am by Emma Snell
Annabelle Timsit and Julie Yoon report for the Washington Post. [read post]
4 Oct 2021, 1:52 pm by Jason Rantanen
Lemley, Erik Oliver, Kent Richardson, James Yoon, & Michael Costa, Patent Purchases and Litigation Outcomes, 2016 Patently-O Patent Law Journal 15 (Lemley.2016.PatentMarket) Bernard Chao and Amy Mapes, An Early Look at Mayo’s Impact on Personalized Medicine, 2016 Patently-O Patent Law Journal 10 (Chao.2016.PersonalizedMedicine) James E. [read post]
4 Oct 2021, 1:52 pm by Jason Rantanen
Lemley, Erik Oliver, Kent Richardson, James Yoon, & Michael Costa, Patent Purchases and Litigation Outcomes, 2016 Patently-O Patent Law Journal 15 (Lemley.2016.PatentMarket) Bernard Chao and Amy Mapes, An Early Look at Mayo’s Impact on Personalized Medicine, 2016 Patently-O Patent Law Journal 10 (Chao.2016.PersonalizedMedicine) James E. [read post]
21 May 2021, 5:54 am
Posted by George Serafeim (Harvard Business School) and Aaron Yoon (Northwestern University), on Monday, May 17, 2021 Tags: Artificial intelligence, Disclosure, Environmental disclosure, ESG, Market reaction, Reputation, SASB The Lipton Archive Posted by Lawrence A. [read post]
29 Mar 2021, 6:30 pm by Jason Rantanen
Lemley, Erik Oliver, Kent Richardson, James Yoon, & Michael Costa, Patent Purchases and Litigation Outcomes, 2016 Patently-O Patent Law Journal 15 (Lemley.2016.PatentMarket) Bernard Chao and Amy Mapes, An Early Look at Mayo’s Impact on Personalized Medicine, 2016 Patently-O Patent Law Journal 10 (Chao.2016.PersonalizedMedicine) James E. [read post]
27 Jan 2021, 11:36 am by Jason Rantanen
Lemley, Erik Oliver, Kent Richardson, James Yoon, & Michael Costa, Patent Purchases and Litigation Outcomes, 2016 Patently-O Patent Law Journal 15 (Lemley.2016.PatentMarket) Bernard Chao and Amy Mapes, An Early Look at Mayo’s Impact on Personalized Medicine, 2016 Patently-O Patent Law Journal 10 (Chao.2016.PersonalizedMedicine) James E. [read post]
27 Dec 2020, 9:06 pm by Series of Essays
Rethinking the Value of a Statistical Life February 10, 2020 | James Broughel, Mercatus Center at George Mason University The value of a statistical life, a popular way to quantify the benefits of mortality risk reduction in cost-benefit analysis, has fundamental and often overlooked flaws that make many of its uses questionable. [read post]